A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications
Tài liệu tham khảo
Köhler, 1975, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256, 495, 10.1038/256495a0
Pescovitz, 2006, Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action, Am. J. Transplant., 6, 859, 10.1111/j.1600-6143.2006.01288.x
Parashar, 2011, Bispecific antibodies for diagnostic applications, 349
Milstein, 1983, Hybrid hybridomas and their use in immunohistochemistry, Nature, 305, 537, 10.1038/305537a0
Nisonoff, 1961, Recombination of a mixture of univalent antibody fragments of different specificity, Arch. Biochem. Biophys., 93, 460, 10.1016/0003-9861(61)90296-X
Kontermann, 2012, Dual targeting strategies with bispecific antibodies, MAbs, 4, 182, 10.4161/mabs.4.2.19000
van Spriel, 2000, Immunotherapeutic perspective for bispecific antibodies, Immunol. Today, 21, 391, 10.1016/S0167-5699(00)01659-5
Stein, 2012, Natural killer (NK)- and T-cell engaging antibody-derived therapeutics, Antibodies, 1, 88, 10.3390/antib1010088
Müller, 2010, Bispecific antibodies for cancer immunotherapy: current perspectives, BioDrugs, 24, 89, 10.2165/11530960-000000000-00000
Wu, 2007, Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin, Nat. Biotechnol., 25, 1290, 10.1038/nbt1345
Kellner, 2008, A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells, J. Immunother., 31, 871, 10.1097/CJI.0b013e318186c8b4
Griffiths, 1993, Human anti-self antibodies with high specificity from phage display libraries, EMBO J., 12, 725, 10.1002/j.1460-2075.1993.tb05706.x
Auf der Maur, 2001, Antigen-independent selection of stable intracellular single-chain antibodies, FEBS Lett., 508, 407, 10.1016/S0014-5793(01)03101-5
Els Conrath, 2001, Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs, J. Biol. Chem., 276, 7346, 10.1074/jbc.M007734200
Holliger, 2005, Engineered antibody fragments and the rise of single domains, Nat. Biotechnol., 23, 1126, 10.1038/nbt1142
Chames, 2009, Bispecific antibodies for cancer therapy: the light at the end of the tunnel?, MAbs, 1, 539, 10.4161/mabs.1.6.10015
Rossi, 2006, Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proc. Natl. Acad. Sci. U.S.A., 103, 6841, 10.1073/pnas.0600982103
Gold, 2008, A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma, Cancer Res., 68, 4819, 10.1158/0008-5472.CAN-08-0232
Orcutt, 2010, A modular IgG-scFv bispecific antibody topology, Protein Eng. Des. Sel., 23, 221, 10.1093/protein/gzp077
Kontermann, 2005, Recombinant bispecific antibodies for cancer therapy, Acta Pharmacol. Sin., 26, 1, 10.1111/j.1745-7254.2005.00008.x
Seimetz, 2010, Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy, Cancer Treat. Rev., 36, 458, 10.1016/j.ctrv.2010.03.001
Buhmann, 2009, Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion, Bone Marrow Transplant., 43, 383, 10.1038/bmt.2008.323
Ruf, 2012, Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model, J. Transl. Med., 10, 219, 10.1186/1479-5876-10-219
Eissler, 2012, Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect, Cancer Res., 72, 3958, 10.1158/0008-5472.CAN-12-0146
Dettmar, 2012, Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM × anti-CD3) treatment in vivo, Clin. Transl. Oncol., 14, 376, 10.1007/s12094-012-0811-5
Hess, 2012, Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity, Future Oncol., 8, 73, 10.2217/fon.11.138
Cardillo, 2004, Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy, Clin. Cancer Res., 10, 3552, 10.1158/1078-0432.CCR-03-0340
Goldenberg, 2006, Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy, J. Clin. Oncol., 24, 823, 10.1200/JCO.2005.03.8471
Sharkey, 2007, Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update, Clin. Cancer Res., 13, 5577s, 10.1158/1078-0432.CCR-07-1087
Tekabe, 2010, Targeting very small model lesions pretargeted with bispecific antibody with 99mTc-labeled high-specific radioactivity polymers, Nucl. Med. Commun., 31, 320, 10.1097/MNM.0b013e32833576e8
Gada, 2011, Pretargeted gamma imaging of murine metastatic melanoma lung lesions with bispecific antibody and radiolabeled polymer drug conjugates, Nucl. Med. Commun., 32, 1231, 10.1097/MNM.0b013e32834af77b
WHO, 2012
Cattamanchi, 2011, Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis, J. Acquir. Immune Defic. Syndr., 56, 230, 10.1097/QAI.0b013e31820b07ab
Davis, 2011, Nucleic acid amplification tests for diagnosis of smear-negative TB in a high HIV-prevalence setting: a prospective cohort study, PLoS ONE, 6, e16321, 10.1371/journal.pone.0016321
Sarkar, 2012, A bispecific antibody based assay shows potential for detecting tuberculosis in resource constrained laboratory settings, PLoS ONE, 7, e32340, 10.1371/journal.pone.0032340
Chen, 2007, Rapid detection of hepatitis B virus surface antigen by an agglutination assay mediated by a bispecific diabody against both human erythrocytes and hepatitis B virus surface antigen, Clin. Vaccine Immunol., 14, 720, 10.1128/CVI.00310-06
Manafi, 2001, Comparative evaluation of different chromogenic/fluorogenic media for detecting Escherichia coli O157:H7 in food, Int. J. Food Microbiol., 71, 257, 10.1016/S0168-1605(01)00610-9
Tang, 2004, Use of bispecific antibodies in molecular velcro assays whose specificity approaches the theoretical limit of immunodetection for Bordetella pertussis, Clin. Diagn. Lab. Immunol., 11, 752, 10.1128/CDLI.11.4.752-757.2004
Tilley, 2000, Detection of Bordetella pertussis in a clinical laboratory by culture, polymerase chain reaction, and direct fluorescent antibody staining; accuracy, and cost, Diagn. Microbiol. Infect. Dis., 37, 17, 10.1016/S0732-8893(00)00117-6
Wagstaffe, 2012, Bispecific antibody-mediated detection of the Staphylococcus aureus thermonuclease, Anal. Chem., 84, 5876, 10.1021/ac203403d
Guan, 2003, Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China, Science, 302, 276, 10.1126/science.1087139
Poon, 2004, The aetiology, origins, and diagnosis of severe acute respiratory syndrome, Lancet Infect. Dis., 4, 663, 10.1016/S1473-3099(04)01172-7
Yam, 2003, Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus, J. Clin. Microbiol., 41, 4521, 10.1128/JCM.41.10.4521-4524.2003
Chan, 2004, Immunofluorescence assay for serologic diagnosis of SARS, Emerg. Infect. Dis., 10, 530, 10.3201/eid1003.030493
Keyaerts, 2005, Growth kinetics of SARS-coronavirus in Vero E6 cells, Biochem. Biophys. Res. Commun., 329, 1147, 10.1016/j.bbrc.2005.02.085
Yamashita, 2005, Susceptibility of human and rat neural cell lines to infection by SARS-coronavirus, Biochem. Biophys. Res. Commun., 334, 79, 10.1016/j.bbrc.2005.06.061
Reichert, 2011, Bispecific antibodies and ADCs: once and future kings?, MAbs, 3, 329, 10.4161/mabs.3.4.16589
Pang, 2007, Diagnostic tests for infectious diseases in the developing world: two sides of the coin, Trans. R. Soc. Trop. Med. Hyg., 101, 856, 10.1016/j.trstmh.2007.04.014
Hemmerle, 2012, A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data, Protein Eng. Des. Sel., 25, 851, 10.1093/protein/gzs061
Dreier, 2003, T Cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct, J. Immunol., 170, 4397, 10.4049/jimmunol.170.8.4397
Dreier, 2002, Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody, Int. J. Cancer, 100, 690, 10.1002/ijc.10557
Loffler, 2003, Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct, Leukemia, 17, 900, 10.1038/sj.leu.2402890
Ren-Heidenreich, 2004, Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model, Cancer, 100, 1095, 10.1002/cncr.20060
Maletz, 2001, Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity, Int. J. Cancer, 93, 409, 10.1002/ijc.1348
Wimberger, 2003, Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody, Int. J. Cancer, 105, 241, 10.1002/ijc.11056
Honemann, 2004, A novel recombinant bispecific single-chain antibody, bscWue-1×CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells, Leukemia, 18, 636, 10.1038/sj.leu.2403264
Grosse-Hovest, 2004, Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing, Proc. Natl. Acad. Sci. U.S.A., 101, 6858, 10.1073/pnas.0308487101
Bruenke, 2004, A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells, Br. J. Haematol., 125, 167, 10.1111/j.1365-2141.2004.04893.x
McCall, 2001, Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity, J. Immunol., 166, 6112, 10.4049/jimmunol.166.10.6112
Haisma, 2000, Targeting of adenoviral vectors through a bispecific single-chain antibody, Cancer Gene Ther., 7, 901, 10.1038/sj.cgt.7700198
Witlox, 2002, Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma, J. Gene Med., 4, 510, 10.1002/jgm.308
Dirven, 2002, Gene therapy for meningioma: improved gene delivery with targeted adenoviruses, J. Neurosurg., 97, 441, 10.3171/jns.2002.97.2.0441
Beusechem, 2002, Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished, J. Virol., 76, 2753, 10.1128/JVI.76.6.2753-2762.2002
Heideman, 2002, Selective gene transfer into primary human gastric tumors using epithelial cell adhesion molecule-targeted adenoviral vectors with ablated native tropism, Hum. Gene Ther., 13, 1677, 10.1089/104303402760293529
Korn, 2004, Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv, J. Gene Med., 6, 642, 10.1002/jgm.555
Cochlovius, 2000, Treatment of human B cell lymphoma xenografts with a CD3×CD19 diabody and T cells, J. Immunol., 165, 888, 10.4049/jimmunol.165.2.888
Kipriyanov, 2002, Synergistic antitumor effect of bispecific CD19×CD3 and CD19×CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma, J. Immunol., 169, 137, 10.4049/jimmunol.169.1.137
Xiong, 2002, Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20×anti-CD3 bispecific diabody, Cancer Lett., 177, 29, 10.1016/S0304-3835(01)00758-3
Hayashi, 2004, A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells, Cancer Immunol. Immunother., 53, 497, 10.1007/s00262-003-0465-9
Gao, 2004, Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein × anti-CD3 diabody, Leukemia, 18, 513, 10.1038/sj.leu.2403267
Schlenzka, 2004, Combined effect of recombinant CD19 × CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma, Anticancer Drugs, 15, 915, 10.1097/00001813-200410000-00013
DeNardo, 2001, Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy, Cancer Biother. Radiopharm., 16, 525, 10.1089/10849780152752128
Leonard, 2008, Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma, Cancer, 113, 2714, 10.1002/cncr.23890
Kipriyanov, 2003, Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies, J. Mol. Biol., 330, 99, 10.1016/S0022-2836(03)00526-6
Korn, 2004, Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes, J. Immunother., 27, 99, 10.1097/00002371-200403000-00003
Nettelbeck, 2001, Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105), Mol. Ther., 3, 882, 10.1006/mthe.2001.0342
Nettelbeck, 2004, Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA, Int. J. Cancer, 108, 136, 10.1002/ijc.11563
Sabine Brüsselbach, 1999, Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody, Tumor Target., 4, 115
Kipriyanov, 1999, Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics, J. Mol. Biol., 293, 41, 10.1006/jmbi.1999.3156
Reusch, 2004, Effect of tetravalent bispecific CD19×CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells, Int. J. Cancer, 112, 509, 10.1002/ijc.20417
Shahied, 2004, Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format, J. Biol. Chem., 279, 53907, 10.1074/jbc.M407888200
Michaelson, 2009, Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR, MAbs, 1, 128, 10.4161/mabs.1.2.7631
Lu, 2004, Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody, J. Biol. Chem., 279, 2856, 10.1074/jbc.M310132200
Dong, 2011, A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity, MAbs, 3, 273, 10.4161/mabs.3.3.15188
Dong, 2010, Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response, Mol. Cancer Ther., 9, 2593, 10.1158/1535-7163.MCT-09-1018
Kuo, 2012, Engineering a CD123×CD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells, Protein Eng. Des. Sel., 25, 561, 10.1093/protein/gzs040
Yazaki, 2013, A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance, Protein Eng. Des. Sel., 26, 187, 10.1093/protein/gzs096
Castoldi, 2013, A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity, Oncogene, 10.1038/onc.2013.245
Asano, 2013, Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody, Protein Eng. Des. Sel., 26, 359, 10.1093/protein/gzt009
Castoldi, 2012, Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties, Protein Eng. Des. Sel., 25, 551, 10.1093/protein/gzs048
Rozan, 2013, Single domain antibody-based and linker-free bispecific antibodies targeting FcgammaRIII induce potent anti-tumor activity without recruiting regulatory T cells, Mol. Cancer Ther., 12, 1481, 10.1158/1535-7163.MCT-12-1012
Feldmann, 2012, Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells, J. Immunol., 189, 3249, 10.4049/jimmunol.1200341
Mabry, 2010, A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo, MAbs, 2, 20, 10.4161/mabs.2.1.10498
Choi, 2013, A novel bispecific antibody recruits T cells to eradicate tumors in the “immunologically privileged” central nervous system, Oncoimmunology, 2, e23639, 10.4161/onci.23639
Choi, 2013, Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma, Proc. Natl. Acad. Sci. U.S.A., 110, 270, 10.1073/pnas.1219817110
Jackman, 2010, Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling, J. Biol. Chem., 285, 20850, 10.1074/jbc.M110.113910
Tam, 2004, A bispecific antibody against human IgE and human FcgammaRII that inhibits antigen-induced histamine release by human mast cells and basophils, Allergy, 59, 772, 10.1111/j.1398-9995.2004.00332.x
Schanzer, 2011, Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains, Antimicrob. Agents Chemother., 55, 2369, 10.1128/AAC.00215-10
Laventie, 2011, Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins, Proc. Natl. Acad. Sci. U.S.A., 108, 16404, 10.1073/pnas.1102265108
De Bernardis, 2007, Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis, J. Infect. Dis., 195, 149, 10.1086/509891
Mabry, 2010, Engineering of stable bispecific antibodies targeting IL-17A and IL-23, Protein Eng. Des. Sel., 23, 115, 10.1093/protein/gzp073
Wu, 2009, Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules, MAbs, 1, 339, 10.4161/mabs.1.4.8755
Bruhl, 2001, Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV, J. Immunol., 166, 2420, 10.4049/jimmunol.166.4.2420
McDonagh, 2012, Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3, Mol. Cancer Ther., 11, 582, 10.1158/1535-7163.MCT-11-0820
Hammer, 2012, CD19 as an attractive target for antibody-based therapy, MAbs, 4, 571, 10.4161/mabs.21338
Stamova, 2012, Cancer immunotherapy by retargeting of immune effector cells via recombinant bispecific antibody constructs, Antibodies, 1, 172, 10.3390/antib1020172
Cioffi, 2012, EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells, Clin. Cancer Res., 18, 465, 10.1158/1078-0432.CCR-11-1270
Huang, 2013, Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation, Cancer Res., 73, 824, 10.1158/0008-5472.CAN-12-1611
Kratz, 2012, Clinical impact of serum proteins on drug delivery, J. Control. Release, 161, 429, 10.1016/j.jconrel.2011.11.028
Dhimolea, 2012, World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA, MAbs, 4, 4, 10.4161/mabs.4.1.18821
Mack, 1997, Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity, J. Immunol., 158, 3965, 10.4049/jimmunol.158.8.3965